- Boston Scientific expects fiscal 2026 earnings to range between $3.43 and $3.49 per share.
- The company reported Q4 net sales of $5.29 billion, up 15.9% year over year and within its guidance range of 14.5% to 16.5%.
- Q4 net income came fell slightly below the company’s forecast of $0.48 to $0.52.
Boston Scientific Corporation (BSX) said on Wednesday that it expects full-year 2026 sales to increase by about 10.5% to 11.5%, lower than the 19.9% increase it reported for full-year 2025.
BSX shares slumped nearly 10% in pre-market trading on Wednesday and fell further after the opening bell. The stock fell to its lowest levels since August 2024.
Boston Scientific expects fiscal 2026 earnings to range between $3.43 and $3.49 per share. For the first quarter, the company projects sales growth of 10.5% to 12.0% and earnings per share of $0.78 to $0.80.
Meanwhile, the company reported Q4 net sales of $5.29 billion, up 15.9% year over year and within its guidance range of 14.5% to 16.5%. It came marginally above Street estimates of $5.28 billion, according to Fiscal.ai data. Net income came in at $0.45 per share, slightly below the company’s forecast of $0.48 to $0.52.
Acquisition Spree
Boston Scientific has been accelerating its acquisition strategy with two major deals last month. The company agreed to acquire Penumbra in a cash-and-stock transaction valued at about $14.5 billion, or $374 per share. Penumbra is known for its mechanical thrombectomy devices that remove blood clots in vascular procedures.
Separately, Boston Scientific is set to acquire Valencia Technologies, a privately held firm focused on treatments for bladder dysfunction, including its implantable eCoin device for urinary incontinence. The Valencia deal is expected to have an immaterial impact on adjusted earnings per share in 2026, though GAAP results may experience short-term dilution from acquisition-related costs.
Retail Reaction
Despite the sharp intraday decline, retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.
One user saw an opportunity to take up fresh positions.
The stock has fallen 18% so far in 2026.
Read also: LLY Stock Surges On Q4 Beat – Obesity, Diabetes Drugs Drive Strong FY26 Outlook
For updates and corrections, email newsroom[at]stocktwits[dot]com.